L-Carnitine for Cardiac Health and Fertility: What 40 Years of Research Shows

L-Carnitine is a quaternary ammonium compound synthesized from lysine and methionine that shuttles long-chain fatty acids into mitochondria for beta-oxidation. Without it, cells cannot efficiently burn fat for energy. The tissues with the highest energy demand — heart, skeletal muscle, and sperm — are most dependent on adequate carnitine status, which is exactly where the supplementation evidence is strongest.

Cardiac Evidence: The Surprising Meta-Analysis

A 2013 systematic review and meta-analysis in Mayo Clinic Proceedings (DiNicolantonio et al., PMID 23597877) pooled 13 controlled trials with 3,629 patients in the setting of acute myocardial infarction. L-carnitine (typically 2–6 g/day) was associated with a 27% reduction in all-cause mortality (RR 0.78, 95% CI 0.60–1.00), a 65% reduction in ventricular arrhythmias (RR 0.35, 95% CI 0.21–0.58), and a 40% reduction in new anginal symptoms (RR 0.60, 95% CI 0.50–0.72). The same meta-analysis found no benefit for incident heart failure or reinfarction, so the signal is concentrated on early electrical and mortality outcomes rather than every cardiac endpoint. Mechanism likely involves restoring fatty acid oxidation in ischemic myocardium, where carnitine levels drop sharply. Despite these findings, carnitine has not entered routine post-MI care — a gap that remains difficult to explain given the safety and cost profile.

Male Fertility Evidence

Cochrane reviews of antioxidants for male subfertility consistently identify carnitine (often combined with acetyl-L-carnitine) as one of the strongest-performing interventions, with significant improvements in sperm motility, concentration, and morphology at doses of 2–3 g/day over 3–6 months. Live birth rate data are weaker due to trial design, but pregnancy rates improve in partners of treated men. Epididymal fluid normally contains carnitine at 2,000× serum concentrations — a clue to its functional importance in sperm maturation.

The TMAO Controversy

Gut bacteria metabolize dietary carnitine to trimethylamine, which the liver oxidizes to TMAO — a metabolite linked observationally to atherosclerosis. This generated headlines suggesting carnitine is cardiotoxic, but controlled trial data continue to show cardioprotective outcomes, suggesting the TMAO hypothesis is not the dominant effect in supplementation contexts. Patients with existing kidney disease should still use carnitine cautiously.

Choosing a Form

L-carnitine tartrate is the most bioavailable oral form for muscle and cardiac outcomes. Acetyl-L-carnitine (ALCAR) crosses the blood-brain barrier and has separate evidence for diabetic neuropathy and age-related cognitive decline. Propionyl-L-carnitine has specific evidence in peripheral arterial disease. The three forms are not interchangeable.